Kymera Nets $45M Milestone, $1.55B Cash Runway and KT-621 Phase 2b Progress
KYMR•Kymera ended Q1 2026 with $1.55 billion in cash securing operations into 2029 and earned a $45 million Gilead milestone for its KT-200 CDK2 degrader program. KT-621 is in 200 and 264-patient Phase 2b trials in atopic dermatitis and eosinophilic asthma with data due mid-2027/late 2027 and FDA Fast Track.
1. Financial Position
Kymera reported $1.55 billion in cash as of March 31, 2026, funding operations into 2029 and recognized a $45 million milestone from Gilead upon exercising its option to license the KT-200 CDK2 molecular glue degrader.
2. STAT6 Degrader KT-621 Progress
The STAT6 degrader KT-621 is enrolled in two Phase 2b trials—a 200-patient BROADEN2 study in moderate to severe atopic dermatitis with topline data expected mid-2027 and a 264-patient BREADTH study in eosinophilic asthma with results due late 2027—and holds FDA Fast Track designation.
3. IRF5 Degrader KT-579 Phase 1
KT-579, an oral IRF5 degrader targeting autoimmune inflammation, is in a Phase 1 healthy volunteer trial with topline safety and biomarker data anticipated in the second half of 2026.
4. Partnership and Pipeline Expansion
Under its Gilead collaboration, Kymera secured a first-in-class oral CDK2 degrader program with an IND planned for 2027, while also advancing early-stage programs supported by robust preclinical toxicology findings.
